Spyre TherapeuticsSYRE
SYRE
About: Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Employees: 65
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
215% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 20
104% more call options, than puts
Call options by funds: $161K | Put options by funds: $79K
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
10% more funds holding
Funds holding: 119 [Q3] → 131 (+12) [Q4]
1.11% more ownership
Funds ownership: 100.89% [Q3] → 102.0% (+1.11%) [Q4]
8% less capital invested
Capital invested by funds: $1.51B [Q3] → $1.39B (-$118M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$45
255%
upside
Avg. target
$45
255%
upside
High target
$45
255%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Leerink Partners Faisal Khurshid 23% 1-year accuracy 3 / 13 met price target | 255%upside $45 | Outperform Initiated | 8 Apr 2025 |
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , April 4, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 93,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").
Neutral
PRNewsWire
3 weeks ago
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-23 monoclonal antibodies Interim pharmacokinetic and safety data from healthy volunteers for SPY003 anticipatedin the second half of 2025 Subject to interim results, Spyre expects to incorporate SPY003 into its planned Phase2 study in ulcerative colitis exploring six investigational monotherapies andcombinations WALTHAM, Mass. , March 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003.
Neutral
PRNewsWire
1 month ago
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , March 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 132,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").
Positive
Seeking Alpha
1 month ago
Spyre Therapeutics: Targeting The Future Of IBD Treatment
Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance sheet with $603.1 million in cash, providing a four-year runway at its current burn rate. SYRE's innovative combination therapy approach targets multiple inflammatory pathways, aiming for better efficacy and long-term disease control in ulcerative colitis.
Neutral
PRNewsWire
1 month ago
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million public offering Continued execution towards expected milestones across portfolio, with interim Phase 1 data readouts for SPY002 and SPY003 on-track for the second quarter and second half of 2025, respectively Remain on track for initiation of Phase 2 platform trial in ulcerative colitis ("UC") in mid-2025 with SPY001 (α4β7), followed by SPY002 (TL1A), SPY003 (IL-23), and combinations thereof, with initial monotherapy results expected in 2026 Announced indication expansion into rheumatoid arthritis ("RA") with SPY002, with expected Phase 2 trial initiation in mid-2025 and top-line results in 2026 $603 million of cash, cash equivalents, and marketable securities as of December 31, 2024, with expected runway into the second half of 2028 WALTHAM, Mass. , Feb. 27, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD") and other immune-mediated diseases, today announced its fourth quarter and full year 2024 financial results and provided program and corporate updates.
Neutral
PRNewsWire
1 month ago
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
WALTHAM, Mass. , Feb. 25, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences: Event: TD Cowen 45th Annual Healthcare Conference Format: Fireside chat and 1x1 meetings Date/Time: Tuesday, March 4, 2025 at 3:10pm ET Location: Boston, MA Event: Jefferies Biotech on the Beach Summit Format: 1x1 meetings Date: Tuesday, March 11, 2025 Location: Miami, FL Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
Neutral
PRNewsWire
1 month ago
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
WALTHAM, Mass. , Feb. 19, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of α4β7 integrin and TL1A cytokine is superior to either monotherapy in mouse models of colitis and coadministration demonstrates no drug-drug effects on exposure in non-human primates (NHPs).
Positive
Zacks Investment Research
2 months ago
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 158.9% upside potential for Spyre Therapeutics (SYRE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
PRNewsWire
2 months ago
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass. , Feb. 7, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 35,000 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").
Neutral
Accesswire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™